Early reversibility to salbutamol does not always predict bronchodilation after salmeterol in stable chronic obstructive pulmonary disease

被引:20
作者
Cazzola, M
Vinciguerra, A
Di Perna, F
Matera, MG
机构
[1] Div. of Pneumology and Allergology, Resp. Clinical Pharmacology Unit, A. Cardarelli Hospital, Naples
[2] Via del Parco Margherita 24
关键词
D O I
10.1016/S0954-6111(98)90347-X
中图分类号
R5 [内科学];
学科分类号
1002 ; 100201 ;
摘要
The assessment of reversibility is recognized as being an essential part of the management of airways obstruction, but testing for reversibility of airways obstruction may not be useful for identifying patients with chronic obstructive pulmonary disease (COPD) who are likely to benefit from bronchodilator treatment. We studied 100 patients with stable COPD. Early reversibility of airways obstruction to 200 mg salbutamol and peak bronchodilation to 50 mu g salmeterol or 200 mu g salbutamol were evaluated in four different sessions (two for salbutamol and two for salmeterol), using a double-blind, cross-over, randomized study. Fifteen minutes after inhalation of salbutamol, 47 patients presented an increase in FEV1 greater than 15% of baseline, whereas 48 showed an increase of FEV1 of at least 160 mi from basal value and 33 an increase in FEV1 greater than both 15% of baseline and 200 mi. On the contrary, 69 patients presented an increase in FEV1 greater than 15% of baseline, 65 an increase of FEV1 of at least 160 mi from basal value and 60 an increase in FEV1 greater than both 15% of baseline and 200 mi as maximum increase over baseline usually 2-4 h after inhalation of salmeterol. Twenty-seven other subjects defined as irreversible by the lack of acute improvement in FEV1 after salbutamol, showed an increase in FEV1 greater than 15% of baseline, 20 showed an increase of FEV1 of at least 160 mi from basal value, and 18 showed an increase in FEV1 greater than both 15% of baseline and 200 mi; all had the maximum degree of bronchodilation usually 1-2 h after salbutamol administration. These findings clearly demonstrate that many patients suffering from stable COPD show early reversibility to a short-acting beta(2)-agonist and patients who do not manifest early reversibility to salbutamol can still benefit from salbutamol or salmeterol. Therefore, treatments with beta(2)-agonists must always be tried.
引用
收藏
页码:1012 / 1016
页数:5
相关论文
共 12 条
[1]  
[Anonymous], 1987, AM REV RESPIR DIS, V136, P225
[2]  
[Anonymous], 1987, Am Rev Respir Dis, V136, P1285
[3]  
CARVERLEY PMA, 1995, CHRONIC OBSTRUCTIVE, P419
[4]   The use of bronchodilators in stable chronic obstructive pulmonary disease [J].
Cazzola, M ;
Spina, D ;
Matera, MG .
PULMONARY PHARMACOLOGY & THERAPEUTICS, 1997, 10 (03) :129-144
[5]   EFFECT OF SALMETEROL AND FORMOTEROL IN PATIENTS WITH CHRONIC OBSTRUCTIVE PULMONARY-DISEASE [J].
CAZZOLA, M ;
SANTANGELO, G ;
PICCOLO, A ;
SALZILLO, A ;
MATERA, MG ;
DAMATO, G ;
ROSSI, F .
PULMONARY PHARMACOLOGY, 1994, 7 (02) :103-107
[6]   ACUTE RESPONSE TO BRONCHODILATOR - AN IMPERFECT GUIDE FOR BRONCHODILATOR THERAPY IN CHRONIC AIR-FLOW LIMITATION [J].
GUYATT, GH ;
TOWNSEND, M ;
NOGRADI, S ;
PUGSLEY, SO ;
KELLER, JL ;
NEWHOUSE, MT .
ARCHIVES OF INTERNAL MEDICINE, 1988, 148 (09) :1949-1952
[7]   THE EFFECT OF ATROPINE INHALATION IN IRREVERSIBLE CHRONIC-BRONCHITIS [J].
MARINI, JJ ;
LAKSHMINARAYAN, S .
CHEST, 1980, 77 (05) :591-596
[8]  
Pearson MG, 1997, THORAX, V52, pS1
[9]  
RENNARD SI, 1996, EUR RESPIR REV, V6, P282
[10]   OPTIMAL ASSESSMENT AND MANAGEMENT OF CHRONIC OBSTRUCTIVE PULMONARY-DISEASE (COPD) [J].
SIAFAKAS, NM ;
VERMEIRE, P ;
PRIDE, NB ;
PAOLETTI, P ;
GIBSON, J ;
HOWARD, P ;
YERNAULT, JC ;
DECRAMER, M ;
HIGENBOTTAM, T ;
POSTMA, DS ;
REES, J .
EUROPEAN RESPIRATORY JOURNAL, 1995, 8 (08) :1398-1420